SI3122775T1 - Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (GDF-15) in njihove uporabe za zdravljenje kahesije pri raku in raka - Google Patents

Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (GDF-15) in njihove uporabe za zdravljenje kahesije pri raku in raka

Info

Publication number
SI3122775T1
SI3122775T1 SI201531059T SI201531059T SI3122775T1 SI 3122775 T1 SI3122775 T1 SI 3122775T1 SI 201531059 T SI201531059 T SI 201531059T SI 201531059 T SI201531059 T SI 201531059T SI 3122775 T1 SI3122775 T1 SI 3122775T1
Authority
SI
Slovenia
Prior art keywords
cancer
gdf
growth
monoclonal antibodies
differentiation factor
Prior art date
Application number
SI201531059T
Other languages
English (en)
Slovenian (sl)
Inventor
Jorg Wischhusen
Markus Junker
Tina Schafer
Dirk Puhringer
Original Assignee
Julius-Maximilians-Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Application filed by Julius-Maximilians-Universitaet Wuerzburg filed Critical Julius-Maximilians-Universitaet Wuerzburg
Publication of SI3122775T1 publication Critical patent/SI3122775T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
SI201531059T 2014-03-26 2015-03-26 Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (GDF-15) in njihove uporabe za zdravljenje kahesije pri raku in raka SI3122775T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Publications (1)

Publication Number Publication Date
SI3122775T1 true SI3122775T1 (sl) 2020-02-28

Family

ID=52745885

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531059T SI3122775T1 (sl) 2014-03-26 2015-03-26 Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (GDF-15) in njihove uporabe za zdravljenje kahesije pri raku in raka

Country Status (22)

Country Link
US (5) US20170204174A1 (OSRAM)
EP (3) EP3653644B1 (OSRAM)
JP (3) JP6865585B2 (OSRAM)
KR (1) KR102520978B1 (OSRAM)
CN (1) CN106536553B (OSRAM)
AU (2) AU2015238264B2 (OSRAM)
BR (1) BR122023027559A2 (OSRAM)
CY (1) CY1122456T1 (OSRAM)
DK (2) DK3653644T5 (OSRAM)
ES (2) ES2965626T3 (OSRAM)
FI (1) FI3653644T3 (OSRAM)
HR (2) HRP20231514T1 (OSRAM)
HU (2) HUE064573T2 (OSRAM)
IL (2) IL248038B (OSRAM)
LT (2) LT3653644T (OSRAM)
NZ (1) NZ724649A (OSRAM)
PL (2) PL3653644T3 (OSRAM)
PT (2) PT3653644T (OSRAM)
RS (1) RS59700B1 (OSRAM)
SI (1) SI3122775T1 (OSRAM)
SM (1) SMT202000064T1 (OSRAM)
WO (1) WO2015144855A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3653644T (lt) 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
EP3197493B1 (en) 2014-09-25 2021-03-10 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
BR112018006218A2 (pt) * 2015-10-02 2018-10-09 Univ Wuerzburg J Maximilians iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
KR102406610B1 (ko) * 2016-07-06 2022-06-08 내셔날 리서치 카운실 오브 캐나다 혈액-뇌 장벽을 통과이동하는 인간화 항체 및 그의 용도
EP3526346A1 (en) * 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
AU2017371382A1 (en) * 2016-12-06 2019-06-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
SG11202101502YA (en) * 2018-08-20 2021-03-30 Pfizer Anti-gdf15 antibodies, compositions and methods of use
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
JP2024511853A (ja) 2021-03-31 2024-03-15 カイマブ・リミテッド Ｇｄｆ１５シグナル伝達の治療的阻害剤
US20250019427A1 (en) 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023217068A1 (zh) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2372119A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
AU2001288770A1 (en) 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
EP2311873B1 (en) * 2004-01-07 2018-08-29 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
PL2441466T3 (pl) 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
CA2694863A1 (en) 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
CN104204218A (zh) 2012-01-26 2014-12-10 安姆根有限公司 生长分化因子15 (gdf-15)多肽
JP2015532271A (ja) * 2012-09-26 2015-11-09 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体
EP3689370A1 (en) 2012-12-21 2020-08-05 Aveo Pharmaceuticals Inc. Anti-gdf15 antibodies
LT3653644T (lt) 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą

Also Published As

Publication number Publication date
JP2017508475A (ja) 2017-03-30
US10604565B2 (en) 2020-03-31
EP3122775A1 (en) 2017-02-01
EP4316596A3 (en) 2024-04-17
US20230382987A1 (en) 2023-11-30
NZ724649A (en) 2022-07-01
AU2020260440B2 (en) 2024-03-21
US20200308264A1 (en) 2020-10-01
DK3122775T3 (da) 2020-02-03
PT3653644T (pt) 2023-12-19
EP4316596A2 (en) 2024-02-07
EP3653644B1 (en) 2023-11-15
CY1122456T1 (el) 2021-01-27
FI3653644T3 (fi) 2023-12-12
EP3653644A1 (en) 2020-05-20
HRP20231514T1 (hr) 2024-03-01
KR20160139005A (ko) 2016-12-06
JP2023098966A (ja) 2023-07-11
JP6865585B2 (ja) 2021-04-28
JP2021119138A (ja) 2021-08-12
IL248038B (en) 2020-08-31
HRP20200034T1 (hr) 2020-03-20
PL3653644T3 (pl) 2024-03-04
BR122023027559A2 (pt) 2024-01-30
WO2015144855A1 (en) 2015-10-01
CA2943694A1 (en) 2015-10-01
EP3122775B1 (en) 2019-11-13
US20170204174A1 (en) 2017-07-20
IL276405B (en) 2021-07-29
LT3122775T (lt) 2020-02-10
PT3122775T (pt) 2019-12-26
BR112016022013A2 (pt) 2017-10-31
DK3653644T5 (da) 2024-08-26
US20200308265A1 (en) 2020-10-01
ES2965626T3 (es) 2024-04-16
JP7607498B2 (ja) 2024-12-27
US20180298091A1 (en) 2018-10-18
US11760795B2 (en) 2023-09-19
PL3122775T3 (pl) 2020-05-18
HUE064573T2 (hu) 2024-03-28
CN106536553B (zh) 2021-03-12
AU2015238264A1 (en) 2016-10-20
LT3653644T (lt) 2024-01-25
AU2015238264B2 (en) 2020-09-03
CN106536553A (zh) 2017-03-22
IL276405A (en) 2020-09-30
DK3653644T3 (da) 2023-12-18
RS59700B1 (sr) 2020-01-31
AU2020260440A1 (en) 2020-11-26
US11634482B2 (en) 2023-04-25
ES2763859T3 (es) 2020-06-01
KR102520978B1 (ko) 2023-04-11
HUE047398T2 (hu) 2020-04-28
IL248038A0 (en) 2016-11-30
SMT202000064T1 (it) 2020-03-13

Similar Documents

Publication Publication Date Title
IL276405B (en) Monoclonal antibodies to factor 15 (gdf-15) for growth and differentiation, and their use for the treatment of cancerous tumors and cancer
IL287051A (en) Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL270596A (en) Antibodies containing heavy constant regions are adapted for use in cancer therapy
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
PT3063173T (pt) Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
IL260474B (en) Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment
IL277861A (en) Antibodies specific to AXL for cancer treatment
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
SG11201704792UA (en) Anti-csf1r antibodies for treating pvns
TWI560201B (en) Bi-specific antibodies for treating cancer
SG11201507354QA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
SG10202002557SA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
GB2524553B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
ZA201707117B (en) Antibody compositions for tumor treatment